Other research analysts have also issued reports about the stock. BTIG Research dropped their price objective on shares of Evolent Health from $36.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, December 3rd. Royal Bank of Canada reduced their price objective on Evolent Health from $20.00 to $17.00 and set an "outperform" rating for the company in a research note on Tuesday, January 14th. Needham & Company LLC initiated coverage on Evolent Health in a research note on Friday, January 10th. They issued a "buy" rating and a $15.00 target price on the stock. Truist Financial cut their price target on Evolent Health from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd. Finally, Oppenheimer lowered their price objective on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $18.38.
Get Our Latest Stock Analysis on EVH
Shares of NYSE:EVH traded up $0.22 during trading on Tuesday, hitting $10.20. 119,540 shares of the company were exchanged, compared to its average volume of 2,309,514. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm's 50 day moving average price is $11.40 and its 200-day moving average price is $20.33. The stock has a market capitalization of $1.19 billion, a P/E ratio of -11.21 and a beta of 1.45. Evolent Health has a 12-month low of $9.74 and a 12-month high of $35.00.
Evolent Health (NYSE:EVH - Get Free Report) last posted its earnings results on Thursday, November 7th. The technology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of $0.30 by ($0.38). The firm had revenue of $621.40 million for the quarter, compared to analyst estimates of $625.58 million. Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. During the same quarter last year, the firm posted $0.19 EPS. On average, research analysts predict that Evolent Health will post 0.26 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the business. Tempus Wealth Planning LLC purchased a new position in shares of Evolent Health during the 4th quarter worth approximately $240,000. Chicago Capital LLC increased its position in Evolent Health by 209.1% during the fourth quarter. Chicago Capital LLC now owns 31,134 shares of the technology company's stock worth $350,000 after buying an additional 21,061 shares in the last quarter. Chicago Partners Investment Group LLC boosted its stake in shares of Evolent Health by 50.0% during the fourth quarter. Chicago Partners Investment Group LLC now owns 13,643 shares of the technology company's stock valued at $153,000 after acquiring an additional 4,547 shares during the last quarter. R Squared Ltd purchased a new stake in Evolent Health during the 4th quarter worth about $31,000. Finally, KBC Group NV raised its stake in Evolent Health by 124.6% in the 4th quarter. KBC Group NV now owns 6,741 shares of the technology company's stock valued at $76,000 after purchasing an additional 3,739 shares during the last quarter.
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.